Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer

Volume: 48, Issue: 2, Pages: 469 - 476
Published: Feb 1, 2021
Abstract
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is used for (re)staging prostate cancer (PCa) and as a biomarker for evaluating response to therapy, but lacks established response criteria. A panel of PCa experts in nuclear medicine, radiology, and/or urology met on February 21, 2020, in Amsterdam, The Netherlands, to formulate criteria for PSMA PET/CT-based response in patients treated for...
Paper Details
Title
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
Published Date
Feb 1, 2021
Volume
48
Issue
2
Pages
469 - 476
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.